Biogen Boosts Profit Forecast with Growth Across Alzheimer's, Rare Disease Portfolio

{
  "signal_id": "58b5f9cb-84c2-2d47-f12c-ba35503b8352",
  "signal_type": "news",
  "signal_subtype": "has_revenue",
  "detected_at": "2026-07-29T17:36:46+00:00",
  "company": {
    "name": "Biogen",
    "domain": "biogen.com"
  },
  "data": {
    "url": "https://www.benzinga.com/markets/earnings/26/07/60772039/biogen-boosts-profit-forecast-with-growth-across-alzheimers-rare-disease-portfolio",
    "title": "Biogen Boosts Profit Forecast with Growth Across Alzheimer's, Rare Disease Portfolio - Benzinga",
    "excerpt": "The Alzheimer’s drug maker reported revenues of $2.736 billion, beating the consensus of $2.458 billion, up 3% on a reported and 2% on a constant currency basis. Spinraza revenue of $402 million, up 2% year-over-year, driven by demand and stocking for the high-dose regimen, partially offset by shipment timing in certain ex-U.S. markets; conversion to the high-dose regimen has been ahead of company expectations in all launched geographies. Vumerity revenue of $197 million, down 7% year-over-year, primarily impacted by inventory dynamics; first half growth of 7% year-over-year. Leqembi (Alzheimer’s drug) revenue was $184 million, with U.S. in-market sales of around $97 million. Revenues from Skyclarys (Friedreich’s ataxia drug), acquired via the Reata acquisition, reached $168 million, up 29%. Zurzuvae’s (postpartum depression drug) revenue of $71 million, up 53%, was driven by demand growth. Biogen completed the acquisition of Apellis, adding Syfovre and Empaveli to its portfolio, which contributed $128 million in revenue and are expected to grow in the mid- to high-teens through 2028. The company raised its fiscal 2026 adjusted earnings guidance from $15.25-$16.25 to $15.85-$16.85, compared to the consensus of $12.83 . Full-year total revenue is now expected to increase by a mid-single-digit percentage for 2026 vs. 2025. Biogen also shared Phase 2 data for BIIB091 in...",
    "summary": "Biogen reported revenues of $2.736 billion, beating the consensus of $2.458 billion.",
    "planning": false,
    "image_url": "https://cdn.benzinga.com/cdn-cgi/image/width=1200,height=800,fit=crop/files/images/story/2026/07/29/Biogen-World-Headquarters-At-225-Binney-.jpg",
    "confidence": 0.95,
    "published_at": "2026-07-29T17:36:46Z",
    "article_sentence": "The Alzheimer’s drug maker reported revenues of $2.736 billion, beating the consensus of $2.458 billion, up 3% on a reported and 2% on a constant currency basis.",
    "amount_normalized": 2736000000000
  }
}

curl https://signals.autobound.ai/v1/signals/58b5f9cb-84c2-2d47-f12c-ba35503b8352 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"biogen.com","limit":20}'